RARX Fails To Impress, LENS Losing Sharpness, DCPH For The Long Haul

The following are some of the biotech stocks in the Day’s Losers list of December 4, 2017.

1. Ra Pharmaceuticals Inc. (RARX)

Lost 37.32% to close Monday’s (Dec.4) trading at $8.92.

News: The Company reported positive interim results from its phase II study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria, or PNH. However, investors seem to be not impressed with the results.

The study consists of three cohorts. Cohort A includes PNH patients who were never treated with Soliris, Cohort B included patients switching from Soliris to RA101495, and Cohort C includes patients who are currently treated with Soliris, but with not much of a response.

Soliris, developed by Alexion Pharmaceuticals Inc. (ALXN) is an approved therapy for PNH.

Paroxysmal nocturnal hemoglobinuria, or PNH, is a condition in which red blood cells break apart prematurely, causing fatigue, shortness of breath and weakness. Blood transfusion is one way of easing the symptoms of this rare disorder. High levels of lactate dehydrogenase in the blood can mean that red blood cells are breaking apart (hemolysis) (Source: AAMDS.org).

In the first cohort of the study, there was rapid, robust, and sustained reduction in lactate dehydrogenase (LDH) levels from baseline to the mean of Weeks 6-12 in patients treated with RA101495 SC. About 50% of patients who were transfusion-dependent prior to enrollment have been transfusion-free since commencing treatment with RA101495 SC.

In the second cohort, when transfusion-independent patients on long-term Soliris therapy, switched to RA101495 SC, they had stable LDH levels and had no episodes of breakthrough hemolysis. However, in the same cohort of patients who were difficult to treat with Soliris and who were transfusion-dependent at baseline switched to RA101495 SC, breakthrough hemolysis occurred in 7 patients, and all 7 had to be reverted to Soliris without complications.

The third cohort has enrolled only three patients, and LDH stabilization and relief of side effects associated with Soliris intolerance have been observed in the first patient enrolled in this cohort.

2. Immunomedics Inc. (IMMU)

Lost 14.12% to close Monday’s trading at $9.00.

News: No news

Near-term catalysts:

–Results of the independent central blinded review along with sensitivity analyses of prior treatment regimens of the phase II study of IMMU-132 in patients with metastatic triple-negative breast cancer are scheduled for presentation on December 7, 2017.
— Submit BLA for IMMU-132 for…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *